Psilocybin, Lp(a), CAC, Niere und Darmkrebs – Evidenz-Quickies KW 12
EvidenzUpdate March 22, 2026 Denis Nößler
A methodologically rigorous randomized controlled trial (EPIsoDE) found that psilocybin did not significantly improve the primary endpoint—a 50% or greater reduction on the HAMD17 depression scale—in patients with treatment-resistant depression. Secondary signals were encouraging but difficult to interpret due to broken blinding and expectation effects. An accompanying editorial and review explain why psychedelics may appear more effective in studies than they actually are.